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Tamoxifen treatment causes an increased risk of endometrial cancer in breast
cancer patients and healthy women taking the drug as a chemopreventive agent.
The mechanisms responsible for tamoxifen-induced carcinogenesis in humans
are presently unknown and there is much interest in identifying whether DNA
damage might be a contributing factor. In rats, hepatocarcinomas arise as a
consequence of high levels of tamoxifen DNA adduct formation in liver tissue.
Furthermore, low levels of tamoxifen DNA binding has been detected in
endometrial and myometrial tissue of women administered a single dose of 14C-
labelled tamoxifen [1]. The major dG-N2-tamoxifen adducts formed in rat liver
have also been reported in endometrial DNA of some patients receiving long-
term tamoxifen treatment [2], although this has not been conﬁrmed by others [3].
Valuable insights into mechanisms of tumour development and the signiﬁcance
of DNA adduct formation can be gained through the analysis of sequence
alterations in the p53 gene of tumours, which can reveal characteristic
mutational signatures.
Preliminary results reported by Welsh and colleagues [4] demonstrated that
endometrial tumours in tamoxifen-treated women contained an excess of
G ﬁ A transitions at non-CpG sites in the p53 gene, compared with tumours in
untreated women. However, these ﬁndings have not been substantiated.
Furthermore, rather than transition mutations, the predominant mutation
induced in transgenic animals by tamoxifen treatment is typically G ﬁ T
transversions. In addition, replication of single dG-N2-tamoxifen adducts in
cultured mammalian cells primarily causes G ﬁ T transversions, although
smaller numbers of G ﬁ A transitions are also evident [5]. In order to clarify
whether tamoxifen induces a characteristic mutation spectrum in human
tumours, we have examined sequence changes in exons 4–9 of p53 in endometrial
tumour samples from six women treated with tamoxifen (20 mg/day) and four
untreated patients, using polymerase chain reaction (PCR) and single-strand
conformation polymorphism (SSCP) analysis.
Current results indicate the presence of sequence alterations in 5/6 samples from
tamoxifen-treated patients and only 1/4 from control patients, as evidenced by
the detection of shifted bands. Potential mutations were detected in exons 4, 5
and 8. Five samples exhibited shifted bands in exon 4, which were extracted from
the SSCP gels and PCR ampliﬁed. Sequence analysis of two samples, from both
a tamoxifen-treated and control patient, revealed the presence of two single base
substitutions, a C ﬁ A transversion located within intron 3 and a G ﬁ C
transversion at codon 72. This G ﬁ C substitution is a common known
polymorphism causing an arginine to proline amino acid change, and was also
observed as the only alteration in a third sample, from a patient that had
received tamoxifen. The remaining two tumours with potential mutations in
exon 4 have yet to be conﬁrmed by sequencing. Only two samples, both from
tamoxifen-treated patients, exhibited mobility shifts in exon 8, each due to the
presence of a single base substitution. One contained a G ﬁ A transition at
codon 273, a common p53 mutational hotspot in many cancers, which would
produce an arginine to histidine amino acid change. The other tumour contained
a G ﬁ T transversion at codon 294 that would substitute a stop codon in place
of a glutamic acid residue. A shifted banding pattern was observed in exon 5 of
just one sample, from a tamoxifen-treated patient and this is currently being
analysed to identify the speciﬁc sequence changes.
Initial results indicate there may be an increased frequency of p53 mutations in
endometrial tumours from tamoxifen-treated women, but this remains to be
conﬁrmed by sequence analysis. Ultimately, the methodology developed in this
pilot study will be used for screening the larger numbers of endometrial tumours
necessary to determine conclusively whether tamoxifen induces characteristic
types and patterns of mutations in the p53 gene.
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